Refund liabilities - Narrative (Details) - EUR (€) € in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2025 |
Dec. 31, 2024 |
Dec. 31, 2023 |
|
| Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
| Refunds provision | € 17,498 | € 26,141 | € 39,941 |
| Current refunds provision | 10,814 | 19,650 | |
| Additions, refund liability | 4,649 | 4,013 | |
| Revenue recognition | 9,985 | 0 | |
| Other releases | 1,117 | 18,922 | |
| Non-current refunds provision | 6,684 | 6,491 | |
| Refund provision, return provision and rebates | 1,800 | 1,100 | |
| Pfizer Inc. | Lyme VLA15 | Amended Collaboration and License agreement | |||
| Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
| Current refunds provision | 9,000 | 18,600 | |
| Additions, refund liability | 3,500 | 2,600 | |
| Revenue recognition | 10,000 | 0 | |
| Other releases | 900 | 18,900 | |
| GSK | Supply agreement | |||
| Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
| Refunds provision | 6,700 | 6,500 | |
| Non-current refunds provision | € 6,700 | € 6,500 | |